Kirill Tarasov

Title: Kirill Tarasov: Innovator in Biomarker Detection

Introduction

Kirill Tarasov is a prominent inventor based in Espoo, Finland. He has made significant contributions to the field of medical diagnostics, particularly in the detection of statin-induced muscle toxicity. With a total of five patents to his name, Tarasov's work is paving the way for more accurate and sensitive diagnostic methods.

Latest Patents

One of Tarasov's latest patents focuses on biomarkers for the sensitive detection of statin-induced muscle toxicity. This invention provides a method for predicting muscle toxicity or its complications, such as myalgia, myopathy, and rhabdomyolysis. By detecting lipid concentrations or lipid ratios in biological samples and comparing them to a control, this method identifies lipid markers that are more specific and sensitive than currently utilized clinical markers. Additionally, the invention includes an antibody targeting these lipids, which can be used for predicting and diagnosing statin-induced muscle toxicity. Furthermore, it relates to kits that comprise lipids and/or antibodies for the prediction and diagnosis of this condition.

Career Highlights

Kirill Tarasov is associated with Zora Biosciences Oy, a company dedicated to advancing biomedical research and diagnostics. His innovative work in the field has garnered attention and respect from peers and industry professionals alike.

Collaborations

Some of his notable coworkers include Reijo Laaksonen and Kim Ekroos, who contribute to the collaborative efforts at Zora Biosciences Oy.

Conclusion

Kirill Tarasov's contributions to the field of biomarker detection are significant and impactful. His innovative methods for diagnosing statin-induced muscle toxicity represent a crucial advancement in medical diagnostics.